Double maintains 1 strategies that include IDYA - IDEAYA Biosciences, Inc.
SeekingAlpha
Delcath's Q4 sales exceeded expectations due to HEPZATO KIT adoption. Discover insights into its profitability, CHOPIN trial impact & 2025 sales forecast.
SeekingAlpha
Ideaya Biosciences, Inc.'s stock faces pressure from macroeconomic shifts and FDA policies, but remains a buy for savvy investors. Click for my IDYA update.
Yahoo
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in the upcoming investor relations events.
Yahoo
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation (BTD) for darovasertib, a potential first-in-class protein kinase C (PKC) inhibitor, for the neoadjuvant treatment of adult patients with primary uveal melanoma (UM) for whom enucleation has been recommended.
Yahoo
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on March 27, 2025, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 17,600 shares of the Company's common stock to a newly hired employee. The stock options were granted under the IDEAYA Biosciences, Inc. 2023 Employment Inducement Incentive Award Plan (202
Yahoo
IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, today announced the publication of abstracts for an oral presentation in the New Drugs on the Horizon series, and three poster presentations on IDE275 (GSK959) at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30, 2025, in Chicago, Illinois. IDE275 (GSK959), a potential best-in-class Werner Helicase (WRN) inhibitor, has demonstrated selective preclinical efficacy in
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
TSN | -0.01% | $21.91B | +8.55% | 3.09% |
DADA | -0.02% | $495.01M | -6.83% | 0.00% |
COP | -0.03% | $134.86B | -19.40% | 3.22% |
TXO | -0.03% | $766.54M | +1.64% | 13.46% |
AMT | -0.03% | $101.86B | +13.31% | 2.85% |
SU | -0.04% | $48.41B | +1.58% | 4.27% |
LBRDA | -0.04% | $12.44B | +63.07% | 0.00% |
DHT | -0.11% | $1.66B | -12.71% | 9.34% |
TME | 0.12% | $10.12B | +26.82% | 0.97% |
HSY | -0.14% | $33.21B | -15.87% | 3.33% |
DVA | 0.15% | $12.34B | +14.04% | 0.00% |
PRPH | -0.17% | $11.65M | -94.11% | 0.00% |
KHC | -0.20% | $36.01B | -19.37% | 5.15% |
GL | 0.23% | $11.08B | +20.01% | 0.75% |
RIO | -0.24% | $75.10B | -7.28% | 6.80% |
EPD | -0.32% | $73.74B | +13.96% | 6.23% |
MUR | 0.33% | $4.26B | -39.61% | 4.75% |
LBRDK | 0.34% | $12.55B | +64.11% | 0.00% |
AWK | -0.36% | $28.51B | +22.92% | 1.99% |
SID | 0.42% | $2.12B | -47.19% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
KRYS | 50.93% | $5.21B | +1.76% | 0.00% |
IMNM | 49.21% | $583.44M | -68.94% | 0.00% |
RCKT | 48.99% | $671.77M | -75.23% | 0.00% |
DNLI | 48.17% | $2.00B | -29.07% | 0.00% |
CRNX | 47.92% | $2.92B | -34.08% | 0.00% |
NTLA | 47.69% | $755.67M | -70.78% | 0.00% |
RYTM | 46.67% | $3.29B | +27.07% | 0.00% |
RVMD | 46.41% | $6.43B | +10.23% | 0.00% |
STOK | 46.09% | $356.91M | -48.50% | 0.00% |
SYRE | 45.42% | $933.38M | -55.31% | 0.00% |
IONS | 45.02% | $4.56B | -34.42% | 0.00% |
CYTK | 44.92% | $4.77B | -43.25% | 0.00% |
SDGR | 44.68% | $1.45B | -20.13% | 0.00% |
VSH | 44.14% | $2.16B | -28.21% | 2.94% |
ROIV | 43.45% | $7.19B | -12.42% | 0.00% |
RXRX | 43.10% | $2.13B | -40.76% | 0.00% |
APGE | 42.78% | $2.25B | -36.95% | 0.00% |
SNDX | 42.67% | $1.12B | -45.48% | 0.00% |
COGT | 42.48% | $651.22M | -16.98% | 0.00% |
KN | 42.42% | $1.34B | -5.22% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BTAL | -37.41% | $416.76M | 1.43% |
VIXY | -35.92% | $195.31M | 0.85% |
TAIL | -27.51% | $87.65M | 0.59% |
TPMN | -21.17% | $33.32M | 0.65% |
UGA | -12.24% | $87.23M | 0.97% |
DBE | -11.62% | $55.52M | 0.77% |
UUP | -10.84% | $325.79M | 0.77% |
JMST | -10.69% | $3.54B | 0.18% |
BNO | -9.90% | $99.25M | 1% |
USCI | -9.47% | $240.82M | 1.07% |
USO | -9.39% | $972.70M | 0.6% |
DBO | -9.02% | $202.41M | 0.77% |
GSG | -8.97% | $1.05B | 0.75% |
USDU | -8.61% | $206.96M | 0.5% |
USL | -8.09% | $47.77M | 0.85% |
CCOR | -7.90% | $64.12M | 1.18% |
PDBC | -7.85% | $4.89B | 0.59% |
COMT | -7.38% | $684.20M | 0.48% |
CTA | -7.16% | $978.30M | 0.76% |
DBC | -7.15% | $1.36B | 0.87% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
XBI | 67.19% | $4.76B | 0.35% |
IBB | 63.33% | $5.61B | 0.45% |
PBE | 58.31% | $224.98M | 0.58% |
GNOM | 57.90% | $47.13M | 0.5% |
RSPA | 56.26% | $292.67M | 0% |
ARKG | 55.06% | $936.86M | 0.75% |
CPRJ | 54.88% | $48.38M | 0.69% |
PTH | 53.60% | $107.91M | 0.6% |
FBT | 53.40% | $1.08B | 0.56% |
BBH | 53.24% | $358.88M | 0.35% |
PINK | 52.46% | $138.92M | 0.5% |
IWC | 52.23% | $797.08M | 0.6% |
QQA | 51.21% | $187.77M | 0% |
IWO | 51.08% | $10.72B | 0.24% |
XPH | 49.38% | $158.14M | 0.35% |
KJUL | 48.60% | $155.05M | 0.79% |
VTWO | 48.51% | $10.92B | 0.07% |
IWM | 48.29% | $62.65B | 0.19% |
ISCG | 47.90% | $655.02M | 0.06% |
KAPR | 47.46% | $144.85M | 0.79% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
CME | -17.56% | $94.61B | +23.82% | 3.89% |
CBOE | -15.96% | $23.50B | +25.53% | 1.05% |
K | -15.91% | $28.46B | +45.70% | 2.75% |
ED | -11.94% | $38.69B | +21.90% | 2.95% |
VZ | -11.45% | $188.34B | +4.44% | 5.84% |
GIS | -11.34% | $32.41B | -14.20% | 3.90% |
T | -10.78% | $201.99B | +59.80% | 3.85% |
CQP | -9.41% | $32.91B | +35.41% | 5.06% |
SCM | -9.37% | - | - | 11.70% |
CPB | -9.21% | $11.75B | -8.27% | 3.73% |
PPC | -8.91% | $11.62B | +59.32% | 0.00% |
EDU | -8.84% | $7.95B | -43.88% | 0.00% |
CCEC | -8.30% | $1.17B | +17.80% | 2.99% |
MO | -8.27% | $96.57B | +35.61% | 6.83% |
CL | -8.26% | $75.88B | +6.19% | 2.07% |
KO | -7.88% | $306.97B | +19.22% | 2.66% |
PRT | -7.51% | $49.92M | -3.00% | 11.26% |
IMO | -7.35% | $37.43B | +1.56% | 2.63% |
TEF | -7.24% | $26.35B | +6.62% | 6.43% |
VLO | -6.03% | $42.02B | -25.92% | 3.65% |
Current Value
$15.151 Year Return
Current Value
$15.151 Year Return
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
KMLM | <0.01% | $218.49M | 0.9% |
IBDQ | 0.14% | $3.17B | 0.1% |
JAAA | 0.16% | $21.29B | 0.21% |
SMB | 0.30% | $265.76M | 0.07% |
DRLL | -0.30% | $304.11M | 0.41% |
IYK | -0.32% | $1.53B | 0.4% |
CMDY | -0.42% | $313.96M | 0.28% |
TBLL | -0.47% | $2.13B | 0.08% |
FTXG | 0.50% | $26.06M | 0.6% |
IXC | 0.69% | $1.83B | 0.41% |
ASHR | 0.86% | $2.63B | 0.65% |
XLE | 0.90% | $33.58B | 0.09% |
PWZ | 0.97% | $703.30M | 0.28% |
AGZD | -1.02% | $134.05M | 0.23% |
GBIL | -1.07% | $6.30B | 0.12% |
FLTR | 1.15% | $2.41B | 0.14% |
BCD | -1.17% | $250.79M | 0.3% |
TAXF | -1.20% | $517.32M | 0.29% |
ICLO | 1.22% | $354.74M | 0.2% |
VTIP | 1.27% | $13.72B | 0.03% |